These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27267873)

  • 1. Rational excipient selection for co-amorphous formulations.
    Korhonen O; Pajula K; Laitinen R
    Expert Opin Drug Deliv; 2017 Apr; 14(4):551-569. PubMed ID: 27267873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.
    Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM
    Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co amorphous systems: A product development perspective.
    Chavan RB; Thipparaboina R; Kumar D; Shastri NR
    Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs.
    Chen X; Stoneburner K; Ladika M; Kuo TC; Kalantar TH
    Appl Spectrosc; 2015 Nov; 69(11):1271-80. PubMed ID: 26647050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of Drug-Excipient Interactions in Biclotymol Amorphous Solid Dispersions.
    Schammé B; Couvrat N; Tognetti V; Delbreilh L; Dupray V; Dargent É; Coquerel G
    Mol Pharm; 2018 Mar; 15(3):1112-1125. PubMed ID: 29328661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
    Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
    Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into co-amorphous systems in therapeutic drug delivery.
    Singh R; Joshi V; Mehetre N; Sangamwar AT
    Ther Deliv; 2021 Mar; 12(3):245-265. PubMed ID: 33745286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
    Widanapathirana L; Tale S; Reineke TM
    Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.
    Qi S; McAuley WJ; Yang Z; Tipduangta P
    Ther Deliv; 2014 Jul; 5(7):817-41. PubMed ID: 25287388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
    Mol Pharm; 2017 Jan; 14(1):157-171. PubMed ID: 28043133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid state drug-polymer miscibility studies using the model drug ABT-102.
    Jog R; Gokhale R; Burgess DJ
    Int J Pharm; 2016 Jul; 509(1-2):285-295. PubMed ID: 27265312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Polymer Type and Relative Humidity on the Long-Term Physical Stability of Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
    Mol Pharm; 2017 Dec; 14(12):4374-4386. PubMed ID: 29050468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Application of Modeling and Prediction to the Formation and Stability of Amorphous Solid Dispersions.
    DeBoyace K; Wildfong PLD
    J Pharm Sci; 2018 Jan; 107(1):57-74. PubMed ID: 28389266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.